- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.08. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 31.08. | SRX Global Inc: SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers | 392 | GlobeNewswire (Europe) | NORTH PALM BEACH, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the "Company" or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value... ► Artikel lesen | |
| 17.07. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.07. | NSE - CERO THERAPEUTICS HOLDINGS, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 1 | SEC Filings | ||
| CERO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 26.06. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.06. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment | 251 | GlobeNewswire (Europe) | Fifth patient treated with CER-1236 underwent stem cell transplant following lack of response to prior therapies; Company initiates third planned cohort in ongoing Phase 1 study in hematologic malignancies... ► Artikel lesen | |
| 29.05. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.05. | CERo Therapeutics: Interview With CEO Chris Ehrlich About The Immunotherapy Company | 2 | pulse2.com | ||
| 11.05. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial | 701 | GlobeNewswire (Europe) | Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosis SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CERo... ► Artikel lesen | |
| 01.05. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 30.04. | CERO THERAPEUTICS HOLDINGS, INC. - 10-K/A, Annual Report | - | SEC Filings | ||
| 15.04. | CERO THERAPEUTICS HOLDINGS, INC. - 10-K, Annual Report | - | SEC Filings | ||
| 14.04. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 14.04. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial | 262 | GlobeNewswire (Europe) | Study will advance into expanded patient populations with myelodysplastic syndrome (MDS) and myelofibrosis (MF) SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings... ► Artikel lesen | |
| 01.04. | CERO THERAPEUTICS HOLDINGS, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
| 30.03. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial | 314 | GlobeNewswire (Europe) | Trial advancing with ongoing safety and pharmacologic evaluation and planned expansion into MDS and MF SOUTH SAN FRANCISCO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc.... ► Artikel lesen | |
| 11.03. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Provides Shareholder Update | 371 | GlobeNewswire (Europe) | Ongoing activities, including new engagement to relist on Nasdaq, new board member, continued advancement of Phase 1 trial into MDS patients, strategic engagement, and continued support from lead... ► Artikel lesen | |
| 07.01. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion-Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML | 244 | GlobeNewswire (Europe) | Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN FRANCISCO, Calif, Jan. 07, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings... ► Artikel lesen | |
| 17.12.25 | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1) | 294 | GlobeNewswire (Europe) | Completion of DLT observation period for Cohort 1; first patient in Cohort 2 dosed at higher cell level; additional dosing in Cohort 1 SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| 02.12.25 | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Trading on OTCQB Market | 282 | GlobeNewswire (Europe) | Company's Shares Will Continue to Trade Under Ticker CERO SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) ("CERo" or the "Company"),... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,209 | +0,21 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,494 | +1,34 % | CytomX auf Morgan Stanley Konferenz: Strategie für fortgeschrittenes Kolorektalkarzinom im Fokus | ||
| CARISMA THERAPEUTICS INC | 0,028 | 0,00 % | United Immunity Acquires Macrophage Assets from Carisma Therapeutics | ||
| CAPRICOR | 7,954 | -3,02 % | Oppenheimer bestätigt Einstufung für Capricor Aktie vor Studiendaten | ||
| CORMEDIX | 6,614 | -0,69 % | CorMedix, Inc.: Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | - Q2 2026 Consolidated Revenue of $101.9 million - - Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million - - Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 3,118 | +3,24 % | Minerva Neurosciences, Inc: Minerva Neurosciences to Participate in Two Upcoming Investor Conferences | BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous... ► Artikel lesen | |
| REPLIMUNE | 10,965 | -2,27 % | Replimune Group, Inc. - 8-K, Current Report | ||
| VALERIO THERAPEUTICS | 0,578 | -7,37 % | Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors | Definitive share purchase agreement signed for the acquisition of 100% of Etherna Immunotherapies NV ("Etherna"), and the related contribution agreement, based on an enterprise value of €30 million... ► Artikel lesen | |
| RANI THERAPEUTICS | 0,843 | 0,00 % | Rani Therapeutics auf H.C. Wainwright Konferenz: Plattform für orale Biologika überzeugt | ||
| IO BIOTECH | 0,048 | 0,00 % | NSE - IO Biotech, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| ALTO NEUROSCIENCE | 30,460 | -1,55 % | Biotech Stocks At 52-Week Highs - Delcath Systems +22% On Q2 Results, Alto Neuroscience, Hemab Therapeutics, Monopar Therapeutics, Nurix Therapeutics | SOUTH SAN FRANCISCO (dpa-AFX) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation.... ► Artikel lesen | |
| OSR HEALTH | 0,113 | -2,75 % | Emerging Growth Research Issues Company-Sponsored Research Flash Report on OSR Health, Inc. | NEW YORK CITY, NY / ACCESS Newswire / August 27, 2026 / Emerging Growth Research, LLC ("Emerging Growth Research" or "EGR") today announced the release of its company-sponsored research flash report... ► Artikel lesen | |
| QIAGEN | 38,410 | -0,51 % | BERENBERG stuft QIAGEN NV auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat Qiagen mit einem Kursziel von 40 Euro auf "Hold" belassen. Der Medizintechnik- und Life-Science-Sektor bleibe fundamental attraktiv, wie die... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 302,51 | -2,56 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,735 | -4,44 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen |
CERO THERAPEUTICS HOLDINGS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,000 (+0,11 %) liegt der Kurs bei 0,095 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERO THERAPEUTICS HOLDINGS INC finden Sie auf Wallstreet Online.